qPCR Instruments Market – By Product Type, By Application, By End-use – Global Forecast, 2024 – 2032

qPCR Instruments Market Size

The global qPCR instruments market size was valued at around USD 1.6 billion in 2023 and is estimated to grow at a CAGR of 8.4% from 2024 to 2032. The increasing prevalence of diseases worldwide and the rising emphasis on personalized medicine are driving the growth of the market.
 

The increasing prevalence of diseases globally is a major factor in this growth, as real-time quantification tools are critical for diagnosing and monitoring infectious diseases, cancer, and genetic disorders. qPCR's ability to provide rapid, accurate results makes it indispensable in disease detection, particularly in regions facing rising rates of infections and chronic conditions. Factors contributing to the increasing prevalence of diseases include urbanization, aging populations, and lifestyle changes that heighten the risk of non-communicable diseases. According to the World Health Organization (WHO), non-communicable diseases now account for 74% of global deaths, increasing the demand for advanced diagnostic tools like qPCR.
 

Additionally, the rising emphasis on personalized medicine is further propelling the qPCR instruments market, as qPCR enables precise genetic profiling and real-time monitoring, which are critical for tailoring treatments to individual patients. Personalized medicine relies on accurate molecular diagnostics to identify genetic mutations and biomarkers, making qPCR an essential tool in optimizing patient care. As the demand for individualized therapies grows, qPCR’s role in drug development, companion diagnostics, and targeted treatments continues to expand, driving market growth.
 

qPCR (quantitative Polymerase Chain Reaction) instruments are advanced laboratory devices used to amplify and simultaneously quantify a specific DNA or RNA sequence in real time. These instruments combine thermal cycling with fluorescence-based detection, enabling accurate quantification of nucleic acids during the amplification process.
 

qPCR Instruments Market Trends

• The market is witnessing several technological advancements that are driving usage trends and are expected to fuel market growth.
   
• Advanced qPCR instruments offer multiplexing, enabling the simultaneous detection of multiple targets in a single reaction. This improves efficiency and reduces costs, particularly in diagnostics and high-throughput applications.
   
• Additionally, the integration of healthcare cloud computing and AI-driven platforms for qPCR data analysis is streamlining workflows. This advancement facilitates remote monitoring, real-time data sharing, and enhanced accuracy in interpreting complex genetic data.
   
• Moreover, new portable qPCR devices are being developed, enabling point-of-care testing in remote or resource-limited settings, increasing accessibility for rapid diagnostics.
   
• Furthermore, the use of nanoparticles is being explored to increase the sensitivity and speed of qPCR reactions. This technology holds promise for detecting ultra-low concentrations of target DNA or RNA, which can be critical in early disease detection or in environments with limited sample availability. These cutting-edge developments are expected to significantly improve the performance, accessibility, and range of applications for qPCR instruments in the coming years.
   

qPCR Instruments Market Analysis

Based on product type, the market is segmented into qPCR systems, reagents & consumables, and software. The qPCR systems segment dominated the market in 2023, accounting for USD 644.2 million.
 

• qPCR systems form the foundation of real-time PCR testing, providing the essential platform for quantitative analysis. These systems enable real-time monitoring of DNA amplification, making them indispensable for qPCR-related applications in diagnostics, research, and drug development.
   
• Additionally, qPCR systems represent the most capital-intensive portion of the market due to the high cost of purchasing and installing these machines in laboratories, hospitals, and clinics. Once acquired, they are consistently used across a range of applications, contributing significantly to revenue. Their recurring demand for upgrades and advanced models further strengthens their market position.
   

Based on application, the qPCR instruments market is segmented into gene expression, genotyping, pathogen detection, diagnostics, and other applications. The gene expression segment dominated the market in 2023 with a market share of 26.6%.
 

• Gene expression analysis is a fundamental tool in molecular biology and biotechnology. It is extensively used to understand gene regulation and expression under various conditions, which is crucial for cancer research, drug development, and understanding disease mechanisms. As a result, there is a consistent and growing demand for qPCR instruments for gene expression studies.
   
• Additionally, with the rising emphasis on personalized medicine, gene expression profiling has gained importance. It helps identify specific biomarkers that guide treatment decisions tailored to individual patients, leading to higher adoption rates in clinical settings and further boosting the demand for qPCR systems for gene expression analysis.

Based on end-use, the qPCR instruments market is segmented into diagnostic laboratories, hospitals & clinics, pharma & biotech companies, and other end-users. The diagnostic laboratories segment is anticipated to reach USD 1.2 billion by 2032.
 

• Diagnostic laboratories are designed for large-scale testing operations and conduct a significant number of qPCR tests daily, especially for molecular diagnostics like infectious disease detection (e.g., COVID-19), cancer screening, and genetic testing. Their high throughput makes them dominant players in the market.
   
• Furthermore, these labs specialize in diagnostic services and invest in advanced, high-throughput qPCR instruments to meet the growing demand for accurate, fast, and large-scale testing.

The North America qPCR instruments market accounted for USD 621 million in revenue in 2023 and is anticipated to grow at a CAGR of 8.1% between 2024 and 2032.
 

• The increasing incidence of infectious diseases such as HIV, influenza, and COVID-19 in North America has heightened the demand for advanced diagnostic tools. qPCR instruments play a crucial role in the rapid and accurate detection of these pathogens, allowing healthcare systems to respond swiftly to outbreaks and manage disease spread more effectively.
   
• Additionally, North America benefits from substantial funding and support for biotechnology and life sciences research from government agencies such as the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA). These investments stimulate innovation and research, driving demand for sophisticated qPCR technologies in both research and clinical settings.
   

The U.S. held a dominant position in the qPCR instruments market, with a revenue of USD 579.3 million in 2023.
 

• The focus on precision oncology and personalized medicine has surged in the U.S., with qPCR playing a critical role in identifying genetic mutations and biomarkers associated with various cancers. This trend drives demand for qPCR instruments, as they are essential for developing targeted therapies and improving patient outcomes through precise genetic profiling.
   
• Moreover, stringent regulations imposed by the Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA) drive the adoption of qPCR in food safety and agricultural biotechnology. qPCR is used for detecting pathogens in food products and for testing genetically modified organisms (GMOs), ensuring compliance with safety standards and regulatory requirements.
   

The UK qPCR instruments market is anticipated to witness substantial growth from 2024 to 2032.
 

• Initiatives such as the 100,000 Genomes Project have significantly advanced genomic research in the UK. The focus on sequencing and analyzing large-scale genetic data drives demand for qPCR instruments, which are essential for validating genetic findings and conducting in-depth research into genetic disorders and diseases.
   
• Furthermore, the UK's proactive approach to monitoring and controlling infectious diseases, particularly in response to outbreaks like COVID-19, has led to increased use of qPCR technology. The National Health Service (NHS) and other public health agencies rely on qPCR for accurate and timely diagnostics, further boosting market demand.
   

Japan holds a dominant position in the Asia-Pacific qPCR instruments market.
 

• Japan has a high incidence of cancer and a strong emphasis on early diagnosis and treatment. qPCR instruments are increasingly used in cancer research and diagnostics to identify genetic markers and mutations, driving their demand in Japanese clinical and research laboratories.
   
• Additionally, the Japanese government's support for precision medicine and personalized healthcare, including initiatives to integrate genomics into clinical practice, has accelerated the adoption of qPCR technology. These policies aim to improve healthcare outcomes through tailored treatments and advanced diagnostic tools, further increasing the demand for qPCR instruments.
   

qPCR Instruments Market Share

The market is fragmented, with a mix of large multinational corporations and numerous small to mid-sized companies competing for market share. The key strategies driving growth in this sector include the development and introduction of innovative qPCR technologies that offer enhanced accuracy, efficiency, and cost-effectiveness. This focus on innovation is crucial for addressing the evolving needs of clinical diagnostics and research while improving patient outcomes. As companies strive to stay competitive, advancements in qPCR technology are pivotal for capturing market share and meeting the increasing demand for sophisticated diagnostic and research tools.
 

qPCR Instruments Market Companies

Some of the eminent market participants operating in the qPCR instruments industry include:

• Abbott Laboratories
• Agilent Technologies, Inc.
• Azure Biosystems Inc.
• Bio Molecular Systems
• BIOMÉRIEUX SA
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Eppendorf
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• QIAGEN N.V.
• Quantabio
• Siemens Healthineers AG
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
   

qPCR Instruments Industry News:

• In September 2024, Takara Bio USA, Inc., a subsidiary of Takara Bio Inc., introduced the SmartChip ND Real-Time PCR System, an automated, high-throughput qPCR solution. This system offers flexibility, allowing users to operate a variety of surveillance panels, enhancing its appeal across multiple applications. With this product launch, Takara Bio aims to strengthen its market position and competitiveness.
   
• In November 2023, Roche launched the LightCycler PRO system, a next-generation qPCR system. This product complements Roche's existing PCR testing portfolio and has contributed to the company's revenue growth by offering enhanced capabilities for real-time PCR testing.
   

qPCR instruments market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• qPCR systems
• Reagents and consumables
• Software

Market, By Application

• Gene expression
• Genotyping
• Pathogen detection
• Diagnostics
• Other applications

Market, By End-users

• Diagnostic laboratories
• Hospitals & clinics
• Pharma & biotech companies
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa